Abstract
The molecular pathways leading to Alzheimer-type dementia are not well understood, but the amyloid beta-protein is believed to be centrally involved. The quantity of amyloid beta-protein containing plaques does not correlate well with clinical status, suggesting that if amyloid beta-protein is pathogenic it involves soluble non-plaque material. Using 43 brains from the Newcastle cohort of the population-representative Medical Research Council Cognitive Function and Ageing Study, we examined the relationship between biochemically distinct forms of amyloid beta-protein and the presence of Alzheimer-type dementia. Cortical samples were serially extracted with Tris-buffered saline, Tris-buffered saline containing 1% TX-100 and with 88% formic acid and extracts analysed for amyloid beta-protein by immunoprecipitation/western blotting. The cohort was divisible into those with dementia at death with (n = 14) or without (n = 10) significant Alzheimer-type pathology, and those who were not demented (n = 19). Amyloid beta-protein monomer in extracts produced using Tris-buffered saline and Tris-buffered saline containing 1% TX-100 were strongly associated with Alzheimer type dementia (P
Original language | English |
---|---|
Pages (from-to) | 1328-1341 |
Number of pages | 14 |
Journal | Brain |
Volume | 133 |
Issue number | 5 |
DOIs | |
Publication status | Published - May 2010 |
Keywords
- Aged
- Aged, 80 and over
- Alzheimer Disease
- Amyloid beta-Peptides
- Blotting, Western
- Cerebral Cortex
- Cohort Studies
- Dementia
- Drug Stability
- Female
- Humans
- Immunoprecipitation
- Male
- Protein Multimerization
- Sodium Dodecyl Sulfate
- Alzheimer's disease pathology
- biochemistry
- cognitive impairment